Lee Henry J, Sinha Animesh A
Department of Dermatology, Weill Medical College of Cornell University, 525 East 68th Street Rm F-340, New York, NY 10021, USA.
Autoimmunity. 2006 Sep;39(6):433-44. doi: 10.1080/08916930600886851.
Cutaneous features of the protean disease lupus erythematous (LE) constitute 4 of 11 diagnostic criteria for systemic lupus erythematosus (SLE) and are exhibited by approximately 3/4 of patients during the course of their disease. Because the pathogenesis of LE is multifactorial and polygenic, many of the details of the pathogenesis remain unclear. We review here the clinical features of cutaneous lupus and recent genetic data that elucidate potential candidate genes for both cutaneous lupus erythematosus (CLE) and SLE. We discuss advances in elucidating the autoimmune pathogenesis of CLE and SLE. Furthermore, promising experimental therapies based on these advances are reviewed in the context of B cell directed therapies, T cell directed therapies, disruption of B and T cell interactions, cytokine directed therapies and finally, end-effector targeted therapies.
多形性疾病红斑狼疮（LE）的皮肤特征构成了系统性红斑狼疮（SLE）11项诊断标准中的4项，约3/4的患者在病程中会出现这些特征。由于LE的发病机制是多因素和多基因的，其发病机制的许多细节仍不清楚。我们在此回顾皮肤型狼疮的临床特征以及最近的遗传学数据，这些数据阐明了皮肤红斑狼疮（CLE）和SLE潜在的候选基因。我们讨论了在阐明CLE和SLE自身免疫发病机制方面的进展。此外，基于这些进展的有前景的实验性疗法将在B细胞导向疗法、T细胞导向疗法、B细胞与T细胞相互作用的阻断、细胞因子导向疗法以及最后效应器靶向疗法的背景下进行综述。
